Development status of non-invasive blood glucose monitoring
Development status of non-invasive blood glucose monitoring – Cheersonic
The “new outlet” of non-invasive blood glucose monitoring has arrived! The device received FDA breakthrough medical device designation
On November 23, HAGAR announced that its non-invasive blood glucose monitoring product GWave received FDA breakthrough medical device designation.
GWave is the world’s first non-invasive continuous glucose monitoring product that uses radio frequency waves (Radio Frequency) to measure glucose levels in the blood. It is one-third the size of a smartphone and uses less radio frequency than a smartphone.
It is worth noting that GWave’s detection technology can realize real-time monitoring of glucose content in blood, avoiding the “common problems” such as high delay and large errors of most real-time monitoring products of interstitial fluid glucose on the market. According to the official introduction, in clinical trials, the accuracy of GWave devices exceeds 95%.
In general, non-invasive blood glucose monitoring has a broad market demand. Especially in my country, which has the largest diabetes population in the world, there are currently more than 140 million diabetic patients, but the proportion of patients who can regularly conduct standardized self-glucose monitoring is very low. Among them, 35.36% of the patients have never conducted self-blood sugar monitoring. Blood sugar monitoring can directly hit the pain points of patients and greatly improve the enthusiasm of diabetic patients for blood sugar monitoring.
However, most current non-invasive blood glucose monitoring products infer blood glucose status based on physiological data, and the database in this field is still to be perfected. In addition, most of the non-invasive blood glucose monitoring products on the market currently monitor blood glucose based on blood substitutes, and it is largely unavoidable that blood glucose fluctuates violently and numerical deviations occur. Therefore, there is still much room for improvement in product monitoring accuracy and biomarker monitoring technology. For diabetic patients, non-invasive blood glucose monitoring is an auxiliary detection method. At present, it is still necessary to judge their own blood glucose indicators based on the “gold standard” of invasive detection of glycosylated hemoglobin.
Cheersonic is the leading developer and manufacturer of ultrasonic coating systems for applying precise, thin film coatings to protect, strengthen or smooth surfaces on parts and components for the microelectronics/electronics, alternative energy, medical and industrial markets, including specialized glass applications in construction and automotive.
